Feeds:
Posts
Comments

Search Results for 'CRISPR'


Doudna and Charpentierand their teams to receive wide-ranging patents in many countries:  European Patent Office (EPO) and UK Intellectual Property Office – broad patent for CRISPR-Cas9 gene-editing technology to the University of California and the University of Vienna Reporter: Aviva Lev-Ari, PhD, RN   The EPO patent will cover the single-guide CRISPR-Cas9 technology in cells of […]

Read Full Post »


Gene Editing Consortium of Biotech Companies: CRISPR Therapeutics $CRSP, Intellia Therapeutics $NTLA, Caribou Biosciences, ERS Genomics, UC, Berkeley (Doudna’s IP) and University of Vienna (Charpentier’s IP), is appealing the decision ruled that there was no interference between the two sides, to the U.S. Court of Appeals for the Federal Circuit, targeting patents from The Broad Institute. […]

Read Full Post »


CRISPR Patent Battle Determined on 2/15/2017 – USPTO issues a verdict in legal tussle over rights to genome-editing technology Curator: Aviva Lev-Ari, PhD, RN Broad Institute prevails in heated dispute over CRISPR patents Sharon Begley sharon.begley@statnews.com @sxbegle In a one-sentence judgment by the Patent Trial and Appeal Board, the three judges decided that there is “no […]

Read Full Post »


Top 50 Women in CRISPR : Women in CRISPR, Legal Status of Inventions and Declaration of the Heroes in CRISPR Curator: Aviva Lev-Ari, PhD, RN   Part 1: Top 50 Women in CRISPR : Women in CRISPR  See List, below SOURCE https://docs.google.com/spreadsheets/u/1/d/10sOQkAg_IKkqozJXqdewiGi6-88W1gnfq5D3g-m22Og/htmlview Part 2: UPDATED – Status “Interference — Initial memorandum” – CRISPR/Cas9 – The […]

Read Full Post »


CRISPR Therapeutics raises a $56M IPO, but patent battles, potential stock drops loom by Ben Adams | Oct 19, 2016 3:52am And then there were three: After Editas ($EDIT) and Intellia ($NTLA) went public this year, CRISPR has brought up the rear with its IPO. But the biotech will need to gear up for a […]

Read Full Post »


“CRISPR-Cas9, bring me a gene,  Encoding for a specific protein: Three words: CRISPR. A Capella Reporter: Aviva Lev-Ari, PhD, RN AROUND FLG Hi Marc , A couple of serious ethical issues have arisen in the genetics news this week. First, a new study has revealed that two major clinical genomic databases show major racial bias towards […]

Read Full Post »


FEBS Journal Special Issue on CRISPR/Cas9 Gene Editing by news.wiley.com Reporter: Aviva Lev-Ari, PhD, RN   FEBS Journal Special Issue on CRISPR FEBS Journal Special Issue on CRISPR/Cas9 The FEBS Journal The discovery of CRISPR in archaea and bacteria The FEBS Journal Design, execution, and analysis of pooled in vitro CRISPR/Cas9 screens The FEBS Journal […]

Read Full Post »


LIVE – The CRISPR/Cas9 Revolution and Gene Editing: 2016 WARREN ALPERT FOUNDATION PRIZE SYMPOSIUM Reporter: Aviva Lev-Ari, PhD, RN Each year the recipient(s) of the Warren Alpert Foundation Prize are recognized at a scientific symposium hosted by Harvard Medical School. OCTOBER 6, 2016 – 1:30PM TO 5:30PM 2016 WARREN ALPERT FOUNDATION PRIZE SYMPOSIUM The CRISPR/Cas9 […]

Read Full Post »


LIVE 9/21 8AM to 10:55 AM Expoloring the Versatility of CRISPR/Cas9 at CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston http://www.discoveryontarget.com/ http://www.discoveryontarget.com/crispr-therapies/ Leaders in Pharmaceutical Business Intelligence (LPBI) Group is a Media Partner of CHI for CHI’s 14th Annual Discovery on Targettaking place September 19 – 22, 2016 in Boston. In Attendance, streaming LIVE using Social Media […]

Read Full Post »


LIVE 9/19 1:40 – 3:20 EMERGING APPLICATIONS OF CRISPR/CAS9 at CHI’s 2nd Annual Symposium CRISPR: Mechanisms and Applications @ CHI’s 14th Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston   CHI’s 2nd Annual Symposium CRISPR: Mechanisms and Applications @ CHI’s 14th  Discovery On Target, 9/19 – 9/22/2016, Westin Boston Waterfront, Boston http://www.discoveryontarget.com/ http://www.discoveryontarget.com/crispr-therapies/ #BostonDOT16 @BostonDOT […]

Read Full Post »

Next »